SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Sanofi has announced an agreement to acquire U.S.-based vaccines company Dynavax Technologies in an all-cash transaction valued at approximately $2.2 billion, marking another strategic move to expand its vaccines business. Under the terms of the deal, Sanofi will pay $15.50 per share, representing a significant premium that drove Dynavax shares up nearly 38% in premarket trading.
The acquisition will be completed through a cash tender offer followed by a squeeze-out merger and is expected to close in the first quarter of 2026, pending regulatory approvals. Sanofi confirmed that the transaction will be funded using existing cash resources and will not impact its financial guidance for 2025, underscoring the company’s strong balance sheet and disciplined capital allocation strategy.
Dynavax’s key asset is HEPLISAV-B, a marketed adult hepatitis B vaccine that requires only two doses over one month, compared with the traditional three-dose regimen over six months used by competing vaccines. This shorter schedule may improve vaccination completion rates, particularly in adult immunization programs. Sanofi highlighted that nearly 100 million adults in the United States born before 1991 remain unvaccinated against hepatitis B, pointing to a sizable market opportunity.
In addition to HEPLISAV-B, the acquisition includes Z-1018, a shingles vaccine candidate currently in phase 1/2 clinical development, along with several early-stage vaccine programs. These assets are expected to strengthen Sanofi’s presence in adult immunization and complement its existing vaccines portfolio.
The deal comes amid heightened investor attention on Sanofi’s research and development pipeline following recent regulatory and clinical setbacks in its multiple sclerosis program, including a Complete Response Letter from the U.S. Food and Drug Administration for tolebrutinib. Sanofi emphasized that the Dynavax acquisition is independent of its multiple sclerosis development efforts.
Analysts at Jefferies described the transaction as a bolt-on acquisition consistent with Sanofi’s long-term strategy, noting that the valuation aligns with expectations and does not change the company’s near-term financial outlook. They also stated there is no negative read-across from Sanofi’s multiple sclerosis challenges to its vaccines business or other pipeline assets.
